Cytek Biosciences (CTKB) Revenue (2020 - 2026)

Cytek Biosciences' Revenue history runs 7 years deep, the most recent figure standing at $44.1 million for Q1 2026.

• Quarterly Revenue rose 6.46% year-over-year to $44.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.2 million (up 3.61% YoY) and the FY2025 annual result came in at $201.5 million, up 0.52% from the prior year.
• Revenue was $44.1 million for Q1 2026 at Cytek Biosciences, down from $62.1 million in the prior quarter.
• Across five years, Revenue topped out at $62.1 million in Q4 2025 and bottomed at $35.1 million in Q1 2022.
• A 5-year average of $47.2 million and a median of $46.6 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 44.46% — and 2025, when it slipped 7.59%.
• Cytek Biosciences' Revenue stood at $48.3 million in 2022, then grew by 20.48% to $58.2 million in 2023, then dropped by 1.3% to $57.5 million in 2024, then gained by 8.12% to $62.1 million in 2025, then fell by 28.98% to $44.1 million in 2026.
• Business Quant data shows CTKB's Revenue at $44.1 million in Q1 2026, $62.1 million in Q4 2025, and $52.3 million in Q3 2025.